Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul 1;16(13):3329-34.
doi: 10.1158/1078-0432.CCR-09-3064. Epub 2010 May 14.

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

Christine A Pratilas  1 , David B Solit
Affiliations
Review

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

Christine A Pratilas et al. Clin Cancer Res. .

Abstract

Mitogen-activated protein kinase (MAPK) pathway activation is a frequent event in human cancer and is often the result of activating mutations in the BRAF and RAS oncogenes. Targeted inhibitors of BRAF and its downstream effectors are in various stages of preclinical and clinical development. These agents offer the possibility of greater efficacy and less toxicity than current therapies for tumors driven by oncogenic mutations in the MAPK pathway. Early clinical results with the BRAF-selective inhibitor PLX4032 suggest that this strategy will prove successful in a select group of patients whose tumors are driven by V600E BRAF. Relief of physiologic feedback upon pathway inhibition may, however, attenuate drug response and contribute to the development of acquired resistance. An improved understanding of the adaptive response of cancer cells to MAPK pathway inhibition may thus aid in the identification of those patients most likely to respond to targeted pathway inhibitors and provide a rational basis for tailored combination strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The RAS-RAF-MEK-ERK signaling pathway
The classical MAP kinase pathway is activated in human tumors by several mechanisms including the binding of ligand to receptor tyrosine kinases (RTKs), mutational activation of an RTK, by loss of the tumor suppressor NF1, or by mutations in RAS, BRAF and MEK1. Phosphorylation and thus activation of ERK regulates transcription of target genes which promote cell cycle progression and tumor survival. The ERK pathway contains a classical feedback loop in which the expression of feedback elements such as SPRY and DUSP family proteins are regulated by the level of ERK activity. Loss of expression of SPRY and DUSP family members due to promoter methylation or deletion is thus permissive for persistently elevated pathway output. In the case of tumors with V600EBRAF expression, pathway output is enhanced by impaired upstream feedback regulation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McCormick F. Signal transduction. How receptors turn Ras on. Nature. 1993;363:15–6. - PubMed
    1. Morrison DK, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol. 1997;9:174–9. - PubMed
    1. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal. 2003;15:463–9. - PubMed
    1. Moodie SA, Willumsen BM, Weber MJ, Wolfman A. Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. Science. 1993;260:1658–61. - PubMed
    1. Catling AD, Schaeffer HJ, Reuter CW, Reddy GR, Weber MJ. A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Mol Cell Biol. 1995;15:5214–25. - PMC - PubMed

MeSH terms

Substances